FDA approves Colorcon’s iron oxide petition to expand colour spectrum

Colorcon, Inc. today announced the FDA’s approval of the Color Additive Petition (21 CFR 73.200) submitted by Colorcon for the use of iron oxide as a colour additive for use in dietary supplement tablets and capsules. The approval will allow the use of iron oxide in dietary supplement tablets and capsules (with a limit of 5 mg, the same as for US regulations for drugs), calculated as elemental iron, per day for labeled dosages, marketed in the United States. Colorcon currently offers a wide palette of colours with thousands of film coating formulation options. This now extends use into dietary supplements and supports the increasing drive for clean labelling.
Colorcon developed this petition in response to increasing requests from dietary supplement manufacturers for more stable pigment options, as they strive to meet consumer demand for more label friendly ingredients in their products. Iron oxides are widely used in the pharmaceutical and food industries around the world and are extremely stable to light and chemical interactions, improving colour stability for the end product. Extending the use of iron oxides into the USA nutritional arena enables an ever wider choice of colour for dietary supplements, providing distinct shades and hues to improve branding and product recognition.
Steve French, of the Natural Marketing Institute (NMI) explained: “As natural products across many product categories continue to gain momentum, it is clearly evident that this global trend is here to stay. This clean label phenomenon has permeated many consumer packaged goods, including dietary supplements and the use of ingredients such as iron oxide, among others, should benefit many manufacturers looking to meet increased consumer demand in the USA.”
The FDA, after their review of Colorcon’s requested amendment, agreed to expand the range of product categories in which iron oxide can be used to include dietary supplement tablets and capsules in the United States.
“We are proud to be instrumental in expanding the use of iron oxides, especially for use in the dietary supplement industry," said Kelly Boyer, Colorcon’s Film Coating General Manager. “These highly stable colorants provide high opacity and good coverage when used for film coating of tablets. They provide a broader colour palette, widening the options available for branding and differentiation when used in combination with other pigments. With our globally recognised colour expertise, Colorcon will successfully utilise iron oxides as colorants across a broad range of dietary supplement applications, bringing an expanded spectrum of colours, with improved stability, to our customers.”
Looking for chemical products? Let suppliers reach out to you!
2026-07-18
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
U.S. Onshoring Debate Exposes API Raw-Material Gap
-
BASF Raises API and Excipient Prices
-
IPEC Updates Excipient Qualification Guidance
-
Pharmaceutical Tariffs Put Ingredients Back in Focus
-
West Asia Tensions Squeeze Pharma Raw Materials
-
Vertex Pushes Gene Therapy Into Younger Children With Blood Disorders
-
Lilly’s Mounjaro Enters China’s State Insurance System
-
A New Obesity Pill Enters the Arena With Double-Digit Weight Loss
-
Wegovy Slips on Price While Mounjaro Defends Its Weight-Loss Crown
Recommend Reading
-
Medicare’s $50 GLP-1 Door Opens: Weight-Loss Drug Demand Just Got Bigger
-
China’s Hybio Takes Generic Tirzepatide to FDA: Lilly’s GLP-1 Fortress Gets a Warning Shot
-
Vertex Buys Crinetics for $10 Billion: Rare Disease M&A Is Back
-
A Faster Route to Diabetes Drug Chemistry
-
AstraZeneca’s Wainua Fails Phase III Heart Trial, Wiping Out About $27 Billion in Market Value
-
Market Conditions Continue to Weaken; Melamine Remains in a Low Range
-
Supply and Demand Pressures Combine, PVC Prices Surge and Then Retreat This Week
-
BDO Market Trend Consolidation and Operation
-
Supply Excess, Acrylonitrile Market Weakens in China
-
Phosphate prices weakened and fell in the first week of July in China (7.1-7.7)